Navigation Links
Golden Meditech Releases FY2008/09 Q3 Results
Date:2/13/2009

HONG KONG, Feb. 13 /PRNewswire-Asia-FirstCall/ -- China's leading integrated medical device and healthcare services provider, Golden Meditech Company Limited ("Golden Meditech" or "the Group"; HKEx: 8180) is pleased to announce today the third quarterly results of financial year 2008/09 for the period ended December 31, 2008. The Group recorded HK$377,707,000 of revenue from key businesses, an increase of 25% on a year-on-year basis.

During the reporting period, the Group's umbilical cord blood bank operations has sustained its strong growth momentum and reported a 71% growth of revenue, accounting for 41% of the Group's total.

Mr. KAM Yuen, Chairman and CEO of Golden Meditech, said the Group's operating profits (excluding investment income(losses) and one-time gains) totaled HK$212,549,000 over the past nine months, representing an increase of 18% over the corresponding period last year. This illustrates the steady and healthy growth and profit-generating capabilities of all key business divisions, he noted.

He attributes the Group's sustained growth to the mounting sales of cord blood bank services and the one-time consumables of ABRS devices, which surged by 71% and 32% respectively. In the initial nine months of this year, the Cord Blood Bank division reported 40% increase of new sign-up customers and contributed up 41% to the Group's total revenue. Medical Device Segment account for 52% of the Group's total.

Over the past nine months, the Group's profits attributable to equity shareholders, however, declined because of increased corporate income tax, absence of one-off exceptional items and losses from investment activities under the impacts of the global financial crisis.

He emphasized that China's healthcare industry will continue to grow despite uncertainties brought to the economy by the global financial crisis. The management has made all efforts to sustain the stable growth of all key businesses, such as enhancing the market development of the umbilical cord blood bank services on one hand, and reinforcing market education to promote clinical applications of the self-developed medical devices, on the other hand.

In alignment with the business expansion, the Group's new storage facilities in Beijing will commence operation on April 1, 2009. By then, the Group will have a combined storage capacity of 600,000 sets of stem cells together with the newly built storage bank in Guangdong Province. These two new facilities will greatly enhance the Group's service capacity in the regions aforementioned.

To accelerate growth of the Medical Device Segment, the management is considering new marketing and sales methods to further penetration of the ABRS devices at hospitals and to encourage the consumable sales as well. In addition, the two new devices, namely, the Plasma Exchange System and the Accelerated Thermostatic Infusion Pump are believed helpful to boost the division's revenue growth and profit in a foreseeable future.

The proposed spin-off and overseas listing of the Group's Cord Blood Bank division won overwhelming shareholders support and was approved at the Extraordinary General Meeting held in Hong Kong on December 15, 2008. Once the transactions are completed, Golden Meditech will become the first hi-tech healthcare company to have successfully spun off and listed its healthcare operations overseas since the establishment of the Growth Enterprise Market in Hong Kong.

Golden Meditech: Founded in 2000 and listed on the Growth Enterprise Market of the Stock Exchange of Hong Kong Limited in December 2001, Golden Meditech is the first hi-tech medical device enterprise that went public outside of the PRC. During the past few years, thanks to its great efforts in innovation and market expansion, as well as its first-mover abilities in capturing the emerging market opportunities, Golden Meditech's medical devices, cord blood banking services and natural herbal medicines have all established dominant positions in their own sectors. Going forward, Golden Meditech will continue its pursuit of becoming China's leading integrated medical group through organic growth, acquisitions and strategic investments.

    For inquiry, please kindly contact:

     Investor Relations Division
     Golden Meditech Company Limited
     Tel:    +852-3605-8138
     Fax:    +852-3605-8181
     Email:  ir@goldenmeditech.com

'/>"/>
SOURCE Golden Meditech Company Limited
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Bellevue Hospital Faces EEOC Race Discrimination Charge, According to Outten & Golden LLP
2. Axium Healthcare Pharmacy, Inc. Has Been Chosen as One of Central Floridas Golden 100 Companies
3. Chicago Sit-In Highlights Laid-Off Workers, Employers Obligations, and WARN Act, According to Outten & Golden LLP
4. Golden Meditech Brings in Financial Investor Through New Share Issuance
5. Golden Meditech Releases FY2008/09 Interim Results
6. Golden Meditech Increases Stakes in Cordlife, Largest Cord Blood Bank Operator in Southeast Asia
7. U.S. Intervenes in False Claims Act Suit Against McKesson Corp. and Golden Horizons Nursing Homes
8. Dataline Announces Participation in Operation Golden Phoenix
9. Golden Meditech Pioneers into Chinas Hospital Market
10. Golden Gate University Opens New Student Services Center
11. Golden Meditech Donates HKD 4 Million to Earthquake Victims
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... ... May 04, 2016 , ... Mother Nature isn’t the only mom ... fruits and vegetables. , Celebrate these women with more than just a bouquet ... with these five garden-themed options. , Vibrant, Edible, Compact Plants from BrazelBerries: , ...
(Date:5/4/2016)... ... May 04, 2016 , ... ... to identify, fund and implement ideas aimed at improving care and reducing readmission ... “Part of our vision for Trinity Health is to drive innovation that transforms ...
(Date:5/4/2016)... ... May 04, 2016 , ... ... and Vancouver, WA, has announced the latest beneficiary of their ongoing community ... and their Mammography Program, which provides free mammograms and diagnostic breast care ...
(Date:5/4/2016)... ... May 04, 2016 , ... The ... research and development of DRACO broad-spectrum antiviral therapeutics. DRACOs have proven effective against ... on May 3, 2016 at http://igg.me/at/EndTheVirus and runs for 60 days, ...
(Date:5/4/2016)... ... May 04, 2016 , ... Nike Rugby Camp's success is due in ... Willis, founder of Elite Rugby Camps and current Nike Camp director, has offered an ... 2009. , “I’m excited for our eighth summer here in San Diego,” says ...
Breaking Medicine News(10 mins):
(Date:5/4/2016)... May 4, 2016 Yissum ... announced today that it had signed an exclusive ... , developer of novel protein degradation and immunomodulatory drugs ... commercialization of drug candidates representing first-in-class therapy for hematologic ... not disclosed. The novel technology was developed ...
(Date:5/4/2016)... 4, 2016 Research ... "Global Multiple Myeloma Market and Competitive Landscape ...      (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ... Competitive Landscape Highlights 2016, provides comprehensive insights ... epidemiology, Multiple Myeloma market valuations and forecast, ...
(Date:5/4/2016)... , May 4, 2016 ... of the  "Global Actinic Keratosis Market and ... their offering.       (Logo: ... Market and Competitive Landscape Highlights 2016, provides ... Actinic Keratosis epidemiology, Actinic Keratosis market valuations ...
Breaking Medicine Technology: